iA Global Asset Management Inc. Decreases Holdings in Amgen Inc. $AMGN

iA Global Asset Management Inc. reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 2.3% during the third quarter, according to its most recent filing with the SEC. The fund owned 62,343 shares of the medical research company’s stock after selling 1,495 shares during the quarter. iA Global Asset Management Inc.’s holdings in Amgen were worth $17,593,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in AMGN. Naples Global Advisors LLC boosted its stake in Amgen by 0.4% in the third quarter. Naples Global Advisors LLC now owns 35,316 shares of the medical research company’s stock valued at $9,966,000 after acquiring an additional 130 shares during the last quarter. Atlas Legacy Advisors LLC raised its holdings in shares of Amgen by 20.7% in the 3rd quarter. Atlas Legacy Advisors LLC now owns 1,544 shares of the medical research company’s stock worth $436,000 after purchasing an additional 265 shares during the period. Leelyn Smith LLC lifted its stake in Amgen by 3.5% in the third quarter. Leelyn Smith LLC now owns 9,554 shares of the medical research company’s stock valued at $2,696,000 after purchasing an additional 324 shares during the last quarter. Covestor Ltd lifted its stake in Amgen by 26.9% in the third quarter. Covestor Ltd now owns 614 shares of the medical research company’s stock valued at $173,000 after purchasing an additional 130 shares during the last quarter. Finally, Accredited Investors Inc. increased its position in Amgen by 5.4% in the third quarter. Accredited Investors Inc. now owns 2,280 shares of the medical research company’s stock worth $643,000 after buying an additional 117 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 10,908 shares of company stock worth $3,674,966. Corporate insiders own 0.76% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent research reports. HSBC reaffirmed a “buy” rating and set a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. Wells Fargo & Company upped their price objective on shares of Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. BMO Capital Markets increased their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. DZ Bank boosted their price target on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Finally, Morgan Stanley dropped their price target on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average target price of $339.24.

Amgen Trading Up 1.0%

Shares of AMGN opened at $347.07 on Friday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $349.98. The stock has a market cap of $186.89 billion, a PE ratio of 26.82, a P/E/G ratio of 3.06 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The business’s 50-day moving average price is $331.91 and its 200-day moving average price is $307.18.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s payout ratio is currently 73.57%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board-approved dividend increase to $2.52, boosting income appeal for dividend investors and supporting demand for the stock. Amgen Announces Dividend Increase
• Positive Sentiment: Amgen expanded its obesity strategy via a collaboration with Ro on GLP‑1 therapies, strengthening its pipeline in high-growth metabolic indications and offering longer-term revenue upside. Amgen Expands Obesity Strategy with Ro Collaboration
• Positive Sentiment: Market momentum: AMGN reached a 52-week high, reflecting strong investor appetite tied to the dividend, pipeline news and overall biotech interest. Amgen Stock Hits 52-Week High
• Positive Sentiment: Analyst/investor bullishness on pipeline: a recent piece highlights MariTide’s obesity/T2D potential as a longer-term growth driver, supporting a constructive buy thesis for 2026+ revenue expansion. Amgen: A Buy In 2026 On MariTide Potential
• Neutral Sentiment: Near-term outlook: coverage noting upcoming earnings and pipeline catalysts — solid fundamentals but investors remain cautious ahead of quarterly reporting. Amgen Stock Outlook and Near-Term Earnings Focus
• Neutral Sentiment: Inclusion in dividend-focused lists (e.g., Dogs of the Dow coverage) underscores income-investor interest but is unlikely to move fundamentals materially. Dogs of the Dow Coverage
• Negative Sentiment: Litigation risk: Sagebrush has sued Amgen over practices related to the 340B program — a regulatory/legal dispute that could create reputational risk, potential fines or contract changes if escalated. Sagebrush Sues Amgen Over 340B Program
• Negative Sentiment: Follow-up coverage analyzing the Sagebrush suit highlights stakeholder friction around 340B — amplifies near-term headline risk that could pressure sentiment if litigation intensifies. Amgen Faces 340B Lawsuit Analysis
• Negative Sentiment: Analyst downgrade: Sanford C. Bernstein lowered AMGN to a Hold, and coverage notes a reduced rating — this can weigh on near-term sentiment despite strong earnings/guidance. Bernstein Downgrades Amgen to Hold

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.